A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete Resection

A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete Resection

Publication date: Jun 10, 2019

The main purpose of study is to compatibility the pharmacokinetic (PK) of Process D relative to Process C.

Concepts Keywords
Adjuvant MRI
Autoimmune Diseases Tomography
Bristol Myers Squibb Magnetic resonance imaging
Cancer Radiation
Computed Tomography Treating cancer
Corticosteroids Radiation therapy
Immunosuppressive Medications Uveal melanoma
Interferon Adjuvant therapy
Magnetic Resonance Imaging Nivolumab
Malignancy Breakthrough therapy
Melanoma Antineoplastic drugs
MRI Cancer
Neurosurgical Bristol-Myers Squibb
PET Scans Melanoma
Pharmacokinetic Health
Positron Emission Tomography Clinical medicine
Radiation Medicine
Radiation Therapy Cancer therapy
Randomization Surgery
Resection Radiation therapy
Uveal Melanoma Autoimmune diseases
Anti cancer
Resected melanoma
Cancers
Cancer therapy
Detectable nodes imaging
Resonance imaging

Semantics

Type Source Name
disease DOID autoimmune disease
disease MESH autoimmune disease
disease DOID uveal melanoma
disease MESH uveal melanoma
gene UNIPROT CYREN
drug DRUGBANK Aspartame
disease DOID cancer
disease MESH cancer
pathway BSID Melanoma
disease DOID Melanoma
disease MESH Melanoma
drug DRUGBANK Nivolumab
gene UNIPROT ALG3
gene UNIPROT NR4A2

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *